LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TOVX
Theriva Biologics, Inc.
There isn't enough reported data to score TOVX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TOVX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TOVX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TOVX PE Valuation
TOVX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TOVX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect TOVX's losses to shrink, with revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus TOVX down 147%.
TOVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$15.42 | +$17.39 |
| Q2 2025 | -$21.78 | +$8.97 |
| Q1 2025 | -$30.60 | -$2.10 |
| Q4 2024 | -$36.55 | -$8.05 |
| Q3 2024 | -$32.81 | +$4.69 |
| Q2 2024 | -$30.75 | +$10.25 |
| Q1 2024 | -$28.50 | +$11.75 |
| Q4 2023 | -$28.50 | +$11.75 |
TOVX is still losing money, but far less than before: $15.42 per share over the past year, against $245.00 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TOVX Quarterly Revenue
TOVX and LLY do not have enough comparable growth data to identify a winner.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -709% | N/A |
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with TOVX at up 24%.
TOVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$1.5M |
| Q1 2026 | -$2.5M | +$2.3M |
| Q4 2025 | -$2.9M | +$1.8M |
| Q3 2025 | -$4.3M | -$425K |
| Q4 2024 | -$4.7M | +$1.9M |
| Q3 2024 | -$3.9M | -$831K |
| Q4 2023 | -$6.6M | -$1.1M |
| Q3 2023 | -$3.1M | +$1.4M |
TOVX has burned cash in almost every quarter: −$13M over the past year, against −$20M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TOVX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TOVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +580% | +39.1M shares |
| 3 years | +7486% | +45.3M shares |
| 5 years | +60249% | +45.8M shares |
| Available history | +69696% | +45.8M shares |
TOVX has 46M diluted shares, up 580% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TOVX Net Leverage
TOVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TOVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 15.7 | Oversold |
TOVX's weekly RSI is 33 (neutral) and its Stochastic is 16 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TOVX PE vs Healthcare Sector
TOVX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TOVX on trend strength, trading above more of its moving averages.
TOVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 20% below |
| 20 week MA | $0.22 | 27% below |
| 50 week MA | $0.23 | 30% below |
| 100 week MA | $0.51 | 69% below |
| 200 week MA | $6.07 | 97% below |
TOVX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TOVX on returns for 2026, with the stronger performance.
TOVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.4 | $94.2 | -28% |
| 2021 | $94.2 | $82.9 | -12% |
| 2022 | $82.9 | $10.5 | -87% |
| 2023 | $10.5 | $10.8 | +2.4% |
| 2024 | $10.8 | $1.47 | -86% |
| 2025 | $1.47 | $0.19 | -87% |
| 2026 YTD | $0.19 | $0.16 | -16% |
TOVX has finished lower in five of the last six years. It's down 16% so far in 2026.